No Data
No Data
US stock market anomaly | Conduit (CDT.US) soared 130% before the market, reaching a drug licensing agreement with AstraZeneca (AZN.US).
Conduit has reached licensing agreements with Astrazeneca for three experimental therapies.
AstraZeneca Licensing Deal Boosts Conduit Pharma
Express News | Conduit Pharmaceuticals Inc - AstraZeneca to Receive Conduit Stock
Conduit Pharmaceuticals Enters Into Exclusive License Agreement With AstraZeneca for Multiple Assets to Advance Potential First-in-Class Treatments
AstraZeneca's AKT inhibitor has begun phase III clinical trials in China.
On August 7th, China's clinical trial registration and information disclosure platform showed that Astrazeneca (AZN.US) has registered a phase III study of the AKT inhibitor Capivasertib in China.
EXCLUSIVE: Penny Stock Conduit Pharmaceuticals Inks Licensing Pact With AstraZeneca For Multiple Assets
No Data